RealWire Limited
Delivering Relevance, Releasing Influence
Issue Date

Release Feed
RSS FeedSpotfire Feed
Share Release
Tweet Facebook LinkedIn
blink it Reddit! Stumble It! Add to Diigo Bookmark this on Delicious
Tweet Facebook LinkedIn
Press Release

WEHI Improves Human Health Through Mastery of Disease Using TIBCO Spotfire Analytics Platform

Australia's First Medical Research Institute to Identify Potential New Drug Therapies More Effectively by Reducing Hit Discovery Time by More Than 65 Percent

SOMERVILLE, MA--(September 13, 2010) -  TIBCO Software Inc. (NASDAQ: TIBX) today announced that Walter and Eliza Hall Institute of Medical Research (WEHI), the first medical research institute to be established in Australia, will employ the TIBCO Spotfire® Analytics Platform to drastically advance its drug discovery process by reducing the time it takes to filter and analyze millions of laboratory test results by more than 65 percent.

Today, life sciences organizations such as WEHI face significant pressure to quickly identify and test potential novel drug therapies. To identify these molecule candidates, WEHI scientists test a bank of more than 350,000 compounds on a daily basis. With TIBCO Spotfire's highly interactive and visual interface, WEHI researchers will be able to quickly and easily spot trends, outliers, and errors in large data volumes of molecular compounds in assay results, and explore real-time hypotheses in various conditions.

Discoveries in the Clinic
With the TIBCO Spotfire Analytics Platform, WEHI is also able to leverage Spotfire's integration with IDBS' ActivityBase™ drug discovery informatics database to:

  • incorporate data from both molecular and cellular screening campaigns to easily identify and exclude problematic trends in data and candidates saving valuable time for better and smarter decision making, and

  • quickly identify candidates and results for follow up to speed up the overall drug discovery process providing a unique competitive edge.

Implementation of TIBCO Spotfire has also assisted WEHI in its public-private partnership role with The Cancer Therapeutics Cooperative Research Centre (CTx CRC). CTx CRC members use Spotfire analytics to analyze the data their laboratory systems produce, delivering similar efficiency improvements on a more specific set of candidate molecules that can be analyzed in-depth by other affiliated researchers.

Supporting Quotes
"With TIBCO Spotfire, our ability to view trends in the data is greatly improved and we are now able to visualize our results in a real-time dashboard, identify and exclude the systematic errors as they occur, and run repeat samples as required," said Dr. Kurt Lackovic, WEHI's senior research officer. "Our ability to report the results to stakeholders has been greatly enhanced in terms of both quality and speed."

"Companies like WEHI serve as a prime example of how valuable TIBCO Spotfire can be to life sciences research organizations," said Ben McGraw, director of life science industry solutions for Spotfire, TIBCO Software Inc. "By giving their scientists the ability to eliminate errors, spot critical trends, and access data in real-time, WEHI can become more nimble and competitive in terms of delivering crucial, new drug therapies to market."

TIBCO Software Inc. (NASDAQ: TIBX) is a leading provider of enterprise analytics software for next generation business intelligence. TIBCO Spotfire products offer a visual and interactive experience that helps professionals quickly discover new and actionable insights in information. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value. Spotfire customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit

TIBCO, TIBCO Software, TIBCO Spotfire, and Spotfire are trademarks or registered trademarks of TIBCO Software Inc. or its subsidiaries in the United States and/or other countries. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.

For further information please contact:
James Cooper or Penny Flood
Ascendant Communications
Tel: +44 (0) 208 334 8041
Email: /